Pinto Susanne, Šajbenová Dominika, Benincà Elisa, Nooij Sam, Terveer Elisabeth M, Keller Josbert J, van der Meulen-de Jong Andrea E, Bogaards Johannes A, Steyerberg Ewout W
Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
J Crohns Colitis. 2025 Feb 4;19(2). doi: 10.1093/ecco-jcc/jjae137.
Fecal microbiota transplantation (FMT) is an experimental treatment for ulcerative colitis (UC). We aimed to study microbial families associated with FMT treatment success.
We analyzed stools from 24 UC patients treated with 4 FMTs weekly after randomization for pretreatment during 3 weeks with budesonide (n = 12) or placebo (n = 12). Stool samples were collected 9 times pre-, during, and post-FMT. Clinical and endoscopic response was assessed 14 weeks after initiation of the study using the full Mayo score. Early withdrawal due to worsening of UC symptoms was classified as non-response.
Nine patients (38%) reached remission at week 14, and 15 patients had a partial response or non-response at or before week 14. With a Dirichlet multinomial mixture model, we identified 5 distinct clusters based on the microbiota composition of 180 longitudinally collected patient samples and 27 donor samples. A Prevotellaceae-dominant cluster was associated with poor response to FMT treatment. Conversely, the families Ruminococcaceae and Lachnospiraceae were associated with a successful clinical response. These associations were already visible at the start of the treatment for a subgroup of patients and were retained in repeated measures analyses of family-specific abundance over time. Responders were also characterized by a significantly lower Simpson dominance compared to non-responders.
The success of FMT treatment of UC patients appears to be associated with specific gut microbiota families, such as control of Prevotellaceae. Monitoring the dynamics of these microbial families could potentially be used to inform treatment success early during FMT.
The study was registered in the Netherlands Trial Register, with reference number NL9858.
粪便微生物群移植(FMT)是溃疡性结肠炎(UC)的一种实验性治疗方法。我们旨在研究与FMT治疗成功相关的微生物科。
我们分析了24例UC患者的粪便,这些患者在随机分组后每周接受4次FMT治疗,在3周的预处理期间分别使用布地奈德(n = 12)或安慰剂(n = 12)。在FMT前、期间和后收集9次粪便样本。在研究开始14周后使用完整的梅奥评分评估临床和内镜反应。因UC症状恶化而提前退出被归类为无反应。
9例患者(38%)在第14周达到缓解,15例患者在第14周或之前有部分反应或无反应。通过狄利克雷多项混合模型,我们根据180份纵向收集的患者样本和27份供体样本的微生物群组成确定了5个不同的聚类。以普雷沃氏菌科为主的聚类与FMT治疗反应不佳相关。相反,瘤胃球菌科和毛螺菌科与成功的临床反应相关。这些关联在治疗开始时对一部分患者就已可见,并在对特定科的丰度随时间的重复测量分析中得以保留。与无反应者相比,反应者的辛普森优势度也显著更低。
UC患者FMT治疗的成功似乎与特定的肠道微生物科有关,如对普雷沃氏菌科的控制。监测这些微生物科的动态变化可能有助于在FMT早期判断治疗是否成功。
该研究已在荷兰试验注册中心注册,注册号为NL9858。